ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-OR085

CKD Progression for Patients with Diabetes and Reduced eGFR Treated with Metformin or Sulfonylurea

Session Information

Category: Diabetic Kidney Disease

  • 602 Diabetic Kidney Disease: Clinical

Authors

  • Hung, Adriana, VA Tennessee Valley healthcare System; Vanderbilt University, Nashville, Tennessee, United States
  • Griffin, Marie, VA Tennessee Valley healthcare System; Vanderbilt University, Nashville, Tennessee, United States
  • Chipman, Jonathan, VA Tennessee Valley healthcare System; Vanderbilt University, Nashville, Tennessee, United States
  • Hackstadt, Amber J., VA Tennessee Valley healthcare System; Vanderbilt University, Nashville, Tennessee, United States
  • Grijalva, Carlos g., VA Tennessee Valley healthcare System; Vanderbilt University, Nashville, Tennessee, United States
  • Greevy, Robert, Vanderbilt University, Nashville, Tennessee, United States
  • Min, Jea young, VA Tennessee Valley healthcare System; Vanderbilt University, Nashville, Tennessee, United States
  • Roumie, Christianne, VA Tennessee Valley healthcare System; Vanderbilt University, Nashville, Tennessee, United States
Background

Safety concerns limit metformin use in kidney disease. We compared the incidence of renal events between metformin and sulfonylureas users with reduced estimated glomerular filtration rate (eGFR).

Methods

A retrospective cohort combined Veterans Administration, Medicare, and National Death Index data. Metformin or sulfonylurea users were followed from renal function threshold (eGFR <60 ml/min/1.73m2) until a renal event, treatment change, loss to follow up, death or study end. Renal event was defined as persistent decline in eGFR from baseline of 40% or more (eGFR event) or a diagnosis of end-stage renal disease (ESRD). The analysis compared renal event hazard for metformin vs. sulfonylurea users and estimate cumulative risk in a propensity score matched weighted cohort accounting for the competing risks of non-persistence or death.

Results

There were 74,101 and 28,976 persistent metformin and sulfonylurea users, respectively, who reached renal threshold. The weighted cohort included 24,886 metformin vs. 24,990 sulfonylurea patients; 98% male; 84% white, median (IQR) age 71 years [64, 78]. Median eGFR was 56 ml/min [51.4, 58.0], 10% of the patients had a eGFR <45 ml/min/1.73m2 and HbA1c 6.6% [6.1, 7.2]. Metformin users had lower cause-specific hazard of renal events vs. sulfonylurea (adjusted HR 0.81, 95%CI (0.68, 0.98)).

Conclusion

Compared to sulfonylureas, metformin use in patients with reduced eGFR was associated with a lower risk of kidney function decline or ESRD.

Funding

  • Veterans Affairs Support